alexa Prognostic factors in 227 patients with malignant fibrous histiocytoma.


Journal of Cancer Science & Therapy

Author(s): Pezzi CM, Rawlings MS Jr, Esgro JJ, Pollock RE, Romsdahl MM

Abstract Share this page

Abstract Malignant fibrous histiocytoma, the major subset of soft tissue sarcomas, was examined for prognostic factors that could influence clinical management and research. Two hundred twenty-seven patients with localized disease, having surgery as the principal modality, were reviewed retrospectively to identify clinical outcomes. The mean age of the patients was 54 years. Extremities were the primary tumor site in 157 patients (62.2\%). Overall survival rate was 50\%, including 38 patients who died of other causes. Distant metastases were most common to the lung (90\%). Local recurrence alone occurred in 37 patients (16\%), distant metastases alone in 52 (23\%), and distant metastases with local recurrence in 25 (11\%). The primary tumor size indicated the 5-year survival rate: tumors smaller than 5 cm had a survival rate of 82\%; 5 to 10 cm, 68\%; and larger than 10 cm, 51\%. Intermediate-grade tumors yielded a 5-year survival rate of 80\%, and the 5-year survival rate for high-grade tumors was 60\%. Survival rates for both grades were affected by size: tumors of high grade and smaller than 5 cm in diameter had a survival rate of 79\%; 5 to 10 cm, 63\%; and more than 10 cm, 41\%. Grade and size emerge as significant prognostic indicators. These variables will prove helpful in treatment decisions and design of clinical studies.
This article was published in Cancer and referenced in Journal of Cancer Science & Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version